WEBVTT
Kind: captions
Language: en
Style:
::cue(c.colorCCCCCC) { color: rgb(204,204,204);
}
::cue(c.colorE5E5E5) { color: rgb(229,229,229);
}
##
00:00:01.540 --> 00:00:08.259 align:start position:0%
[Music]
00:00:08.259 --> 00:00:08.269 align:start position:0%
[Music]
00:00:08.269 --> 00:00:10.430 align:start position:0%
[Music]
welcome<00:00:09.269> to<00:00:09.480> the<00:00:09.570> daily<00:00:09.719> highlights<00:00:09.929> videos
00:00:10.430 --> 00:00:10.440 align:start position:0%
welcome to the daily highlights videos
00:00:10.440 --> 00:00:13.190 align:start position:0%
welcome to the daily highlights videos
from<00:00:10.740> the<00:00:10.950> ers<00:00:11.519> my<00:00:12.240> name<00:00:12.389> is<00:00:12.509> Neil<00:00:12.660> Martin<00:00:12.900> I'm
00:00:13.190 --> 00:00:13.200 align:start position:0%
from the ers my name is Neil Martin I'm
00:00:13.200 --> 00:00:14.959 align:start position:0%
from the ers my name is Neil Martin I'm
one<00:00:13.380> of<00:00:13.500> the<00:00:13.620> global<00:00:13.889> medical<00:00:14.280> experts<00:00:14.759> who
00:00:14.959 --> 00:00:14.969 align:start position:0%
one of the global medical experts who
00:00:14.969 --> 00:00:18.080 align:start position:0%
one of the global medical experts who
works<00:00:15.150> for<00:00:15.330> GSK<00:00:15.780> and<00:00:16.049> I'm<00:00:16.470> joined<00:00:16.740> by<00:00:17.130> today
00:00:18.080 --> 00:00:18.090 align:start position:0%
works for GSK and I'm joined by today
00:00:18.090 --> 00:00:19.519 align:start position:0%
works for GSK and I'm joined by today
but<00:00:18.300> with<00:00:18.449> my<00:00:18.570> colleague<00:00:18.900> Emilio<00:00:19.380> please
00:00:19.519 --> 00:00:19.529 align:start position:0%
but with my colleague Emilio please
00:00:19.529 --> 00:00:22.000 align:start position:0%
but with my colleague Emilio please
zucchini<00:00:19.920> one<00:00:20.400> of<00:00:20.490> our<00:00:20.609> Jimmy's<00:00:21.029> from<00:00:21.330> Brazil
00:00:22.000 --> 00:00:22.010 align:start position:0%
zucchini one of our Jimmy's from Brazil
00:00:22.010 --> 00:00:24.830 align:start position:0%
zucchini one of our Jimmy's from Brazil
we<00:00:23.010> both<00:00:23.189> went<00:00:23.400> to<00:00:23.730> a<00:00:24.029> lunchtime<00:00:24.390> session
00:00:24.830 --> 00:00:24.840 align:start position:0%
we both went to a lunchtime session
00:00:24.840 --> 00:00:27.290 align:start position:0%
we both went to a lunchtime session
today<00:00:25.140> which<00:00:25.470> was<00:00:25.650> run<00:00:25.890> based<00:00:26.640> around<00:00:26.880> new
00:00:27.290 --> 00:00:27.300 align:start position:0%
today which was run based around new
00:00:27.300 --> 00:00:29.540 align:start position:0%
today which was run based around new
biologic<00:00:27.840> agents<00:00:28.320> for<00:00:28.560> severe<00:00:28.830> asthma
00:00:29.540 --> 00:00:29.550 align:start position:0%
biologic agents for severe asthma
00:00:29.550 --> 00:00:30.890 align:start position:0%
biologic agents for severe asthma
I<00:00:29.580> mean<00:00:30.330> though<00:00:30.449> there<00:00:30.570> was<00:00:30.660> a<00:00:30.689> lot<00:00:30.750> of
00:00:30.890 --> 00:00:30.900 align:start position:0%
I mean though there was a lot of
00:00:30.900 --> 00:00:33.520 align:start position:0%
I mean though there was a lot of
discussion<00:00:31.590> and<00:00:31.769> the<00:00:32.239> seminar<00:00:33.239> today
00:00:33.520 --> 00:00:33.530 align:start position:0%
discussion and the seminar today
00:00:33.530 --> 00:00:36.590 align:start position:0%
discussion and the seminar today
starting<00:00:34.530> with<00:00:34.559> Sally<00:00:35.190> Wenzel<00:00:35.640> who<00:00:36.390> went
00:00:36.590 --> 00:00:36.600 align:start position:0%
starting with Sally Wenzel who went
00:00:36.600 --> 00:00:38.389 align:start position:0%
starting with Sally Wenzel who went
through<00:00:36.719> then<00:00:37.079> an<00:00:37.230> overview<00:00:37.649> of<00:00:37.739> the<00:00:37.860> biology
00:00:38.389 --> 00:00:38.399 align:start position:0%
through then an overview of the biology
00:00:38.399 --> 00:00:40.430 align:start position:0%
through then an overview of the biology
of<00:00:38.430> all<00:00:38.700> the<00:00:38.820> different<00:00:39.090> biologic<00:00:39.570> agents<00:00:39.960> and
00:00:40.430 --> 00:00:40.440 align:start position:0%
of all the different biologic agents and
00:00:40.440 --> 00:00:41.690 align:start position:0%
of all the different biologic agents and
one<00:00:40.770> of<00:00:40.829> the<00:00:40.890> things<00:00:41.010> that<00:00:41.100> really<00:00:41.160> stood<00:00:41.550> out
00:00:41.690 --> 00:00:41.700 align:start position:0%
one of the things that really stood out
00:00:41.700 --> 00:00:44.209 align:start position:0%
one of the things that really stood out
to<00:00:41.879> me<00:00:41.910> was<00:00:42.210> the<00:00:42.239> importance<00:00:43.050> of<00:00:43.170> the<00:00:43.680> presence
00:00:44.209 --> 00:00:44.219 align:start position:0%
to me was the importance of the presence
00:00:44.219 --> 00:00:45.650 align:start position:0%
to me was the importance of the presence
or<00:00:44.309> absence<00:00:44.489> of<00:00:44.879> ES<00:00:45.180> and<00:00:45.239> a<00:00:45.390> filling
00:00:45.650 --> 00:00:45.660 align:start position:0%
or absence of ES and a filling
00:00:45.660 --> 00:00:48.979 align:start position:0%
or absence of ES and a filling
inflammation<00:00:46.320> in<00:00:46.980> severe<00:00:47.789> asthma<00:00:48.210> what<00:00:48.870> was
00:00:48.979 --> 00:00:48.989 align:start position:0%
inflammation in severe asthma what was
00:00:48.989 --> 00:00:52.510 align:start position:0%
inflammation in severe asthma what was
your<00:00:49.110> take<00:00:49.320> on<00:00:49.500> that<00:00:49.680> well<00:00:49.950> I<00:00:50.910> think<00:00:51.180> sister
00:00:52.510 --> 00:00:52.520 align:start position:0%
your take on that well I think sister
00:00:52.520 --> 00:00:54.889 align:start position:0%
your take on that well I think sister
the<00:00:53.520> research<00:00:54.149> that<00:00:54.180> start<00:00:54.809> with
00:00:54.889 --> 00:00:54.899 align:start position:0%
the research that start with
00:00:54.899 --> 00:00:57.770 align:start position:0%
the research that start with
bronchoscopy<00:00:55.829> and<00:00:56.670> this<00:00:57.300> has<00:00:57.539> been
00:00:57.770 --> 00:00:57.780 align:start position:0%
bronchoscopy and this has been
00:00:57.780 --> 00:01:00.560 align:start position:0%
bronchoscopy and this has been
highlighted<00:00:58.440> in<00:00:59.039> the<00:00:59.190> meeting<00:00:59.520> that<00:00:59.730> we
00:01:00.560 --> 00:01:00.570 align:start position:0%
highlighted in the meeting that we
00:01:00.570 --> 00:01:04.009 align:start position:0%
highlighted in the meeting that we
understood<00:01:01.320> that<00:01:01.579> asthma<00:01:02.579> is<00:01:03.019> heterogeneous
00:01:04.009 --> 00:01:04.019 align:start position:0%
understood that asthma is heterogeneous
00:01:04.019 --> 00:01:07.070 align:start position:0%
understood that asthma is heterogeneous
disease<00:01:04.400> some<00:01:05.400> patients<00:01:05.909> have<00:01:06.060> asthma<00:01:06.810> that
00:01:07.070 --> 00:01:07.080 align:start position:0%
disease some patients have asthma that
00:01:07.080 --> 00:01:10.130 align:start position:0%
disease some patients have asthma that
is<00:01:07.439> rich<00:01:07.740> in<00:01:08.040> the<00:01:08.250> original<00:01:08.549> field<00:01:08.820> aged<00:01:09.299> too
00:01:10.130 --> 00:01:10.140 align:start position:0%
is rich in the original field aged too
00:01:10.140 --> 00:01:12.560 align:start position:0%
is rich in the original field aged too
high<00:01:10.439> and<00:01:10.770> some<00:01:11.430> patients<00:01:11.820> have<00:01:11.939> an<00:01:12.180> asthma
00:01:12.560 --> 00:01:12.570 align:start position:0%
high and some patients have an asthma
00:01:12.570 --> 00:01:14.390 align:start position:0%
high and some patients have an asthma
that<00:01:12.750> does<00:01:13.080> not<00:01:13.320> have<00:01:13.619> the<00:01:13.860> zeal<00:01:14.070> of<00:01:14.159> yours
00:01:14.390 --> 00:01:14.400 align:start position:0%
that does not have the zeal of yours
00:01:14.400 --> 00:01:17.899 align:start position:0%
that does not have the zeal of yours
what<00:01:15.360> you<00:01:15.570> have<00:01:15.750> understood<00:01:16.320> also<00:01:16.619> that<00:01:17.100> there
00:01:17.899 --> 00:01:17.909 align:start position:0%
what you have understood also that there
00:01:17.909 --> 00:01:19.609 align:start position:0%
what you have understood also that there
are<00:01:18.030> critical<00:01:18.479> characters<00:01:18.990> that<00:01:19.320> may
00:01:19.609 --> 00:01:19.619 align:start position:0%
are critical characters that may
00:01:19.619 --> 00:01:21.260 align:start position:0%
are critical characters that may
differentiate<00:01:20.070> those<00:01:20.580> in<00:01:20.759> the<00:01:20.850> physical
00:01:21.260 --> 00:01:21.270 align:start position:0%
differentiate those in the physical
00:01:21.270 --> 00:01:24.770 align:start position:0%
differentiate those in the physical
model<00:01:21.600> to<00:01:21.780> the<00:01:21.900> FIDIC<00:01:22.170> asthma<00:01:22.590> but<00:01:23.040> mostly<00:01:23.780> we
00:01:24.770 --> 00:01:24.780 align:start position:0%
model to the FIDIC asthma but mostly we
00:01:24.780 --> 00:01:27.350 align:start position:0%
model to the FIDIC asthma but mostly we
need<00:01:25.020> to<00:01:25.140> use<00:01:25.350> a<00:01:25.380> biomarker<00:01:25.979> to<00:01:26.340> predict<00:01:26.759> to
00:01:27.350 --> 00:01:27.360 align:start position:0%
need to use a biomarker to predict to
00:01:27.360 --> 00:01:30.380 align:start position:0%
need to use a biomarker to predict to
understand<00:01:28.130> what<00:01:29.130> kind<00:01:29.610> of<00:01:29.790> asthma<00:01:30.210> those
00:01:30.380 --> 00:01:30.390 align:start position:0%
understand what kind of asthma those
00:01:30.390 --> 00:01:33.679 align:start position:0%
understand what kind of asthma those
patients<00:01:30.900> have<00:01:31.310> the<00:01:32.310> biomarkers<00:01:33.270> that<00:01:33.450> have
00:01:33.679 --> 00:01:33.689 align:start position:0%
patients have the biomarkers that have
00:01:33.689 --> 00:01:36.170 align:start position:0%
patients have the biomarkers that have
been<00:01:33.900> spoken<00:01:34.259> about<00:01:34.560> where<00:01:35.189> you<00:01:35.430> know<00:01:35.790> fuse
00:01:36.170 --> 00:01:36.180 align:start position:0%
been spoken about where you know fuse
00:01:36.180 --> 00:01:39.190 align:start position:0%
been spoken about where you know fuse
fuse<00:01:36.450> oh<00:01:36.659> and<00:01:36.900> blood<00:01:37.340> Perry<00:01:38.340> Austin<00:01:38.820> and
00:01:39.190 --> 00:01:39.200 align:start position:0%
fuse oh and blood Perry Austin and
00:01:39.200 --> 00:01:43.219 align:start position:0%
fuse oh and blood Perry Austin and
phenyl<00:01:40.490> and<00:01:41.490> so<00:01:42.270> Elizabeth<00:01:42.630> Bell<00:01:42.810> then<00:01:43.020> gave
00:01:43.219 --> 00:01:43.229 align:start position:0%
phenyl and so Elizabeth Bell then gave
00:01:43.229 --> 00:01:45.109 align:start position:0%
phenyl and so Elizabeth Bell then gave
the<00:01:43.380> second<00:01:43.799> table<00:01:44.009> looking<00:01:44.820> at<00:01:45.000> the
00:01:45.109 --> 00:01:45.119 align:start position:0%
the second table looking at the
00:01:45.119 --> 00:01:47.630 align:start position:0%
the second table looking at the
translational<00:01:46.020> science<00:01:46.560> so<00:01:47.280> we<00:01:47.399> have<00:01:47.520> this
00:01:47.630 --> 00:01:47.640 align:start position:0%
translational science so we have this
00:01:47.640 --> 00:01:50.510 align:start position:0%
translational science so we have this
range<00:01:47.970> of<00:01:48.270> biomarkers<00:01:48.990> which<00:01:49.200> indicate<00:01:50.009> th2
00:01:50.510 --> 00:01:50.520 align:start position:0%
range of biomarkers which indicate th2
00:01:50.520 --> 00:01:52.760 align:start position:0%
range of biomarkers which indicate th2
high<00:01:50.700> disease<00:01:51.030> as<00:01:51.180> you<00:01:51.210> say<00:01:51.479> but<00:01:52.229> it<00:01:52.320> was<00:01:52.470> clear
00:01:52.760 --> 00:01:52.770 align:start position:0%
high disease as you say but it was clear
00:01:52.770 --> 00:01:55.399 align:start position:0%
high disease as you say but it was clear
that<00:01:52.799> the<00:01:53.250> presence<00:01:54.060> or<00:01:54.149> absence<00:01:54.299> of<00:01:54.810> a<00:01:55.170> high
00:01:55.399 --> 00:01:55.409 align:start position:0%
that the presence or absence of a high
00:01:55.409 --> 00:01:58.069 align:start position:0%
that the presence or absence of a high
blood<00:01:55.829> is<00:01:56.100> of<00:01:56.369> a<00:01:56.490> kind<00:01:56.729> seemed<00:01:57.450> to<00:01:57.659> determine
00:01:58.069 --> 00:01:58.079 align:start position:0%
blood is of a kind seemed to determine
00:01:58.079 --> 00:01:59.300 align:start position:0%
blood is of a kind seemed to determine
response<00:01:58.409> to<00:01:58.560> therapy<00:01:58.710> in<00:01:58.920> other<00:01:59.009> words<00:01:59.159> it
00:01:59.300 --> 00:01:59.310 align:start position:0%
response to therapy in other words it
00:01:59.310 --> 00:02:01.429 align:start position:0%
response to therapy in other words it
was<00:01:59.430> a<00:01:59.460> predictive<00:02:00.090> biomarker<00:02:00.810> for<00:02:00.990> these
00:02:01.429 --> 00:02:01.439 align:start position:0%
was a predictive biomarker for these
00:02:01.439 --> 00:02:04.039 align:start position:0%
was a predictive biomarker for these
patients<00:02:01.619> responding<00:02:02.250> to<00:02:02.340> biologics<00:02:03.049> yet
00:02:04.039 --> 00:02:04.049 align:start position:0%
patients responding to biologics yet
00:02:04.049 --> 00:02:05.990 align:start position:0%
patients responding to biologics yet
understand<00:02:04.710> the<00:02:04.770> road<00:02:05.040> about<00:02:05.369> civilians<00:02:05.880> in
00:02:05.990 --> 00:02:06.000 align:start position:0%
understand the road about civilians in
00:02:06.000 --> 00:02:07.459 align:start position:0%
understand the road about civilians in
the<00:02:06.119> field<00:02:06.299> chiasma<00:02:06.780> it's<00:02:06.960> mainly<00:02:07.290> about
00:02:07.459 --> 00:02:07.469 align:start position:0%
the field chiasma it's mainly about
00:02:07.469 --> 00:02:09.199 align:start position:0%
the field chiasma it's mainly about
understanding<00:02:08.429> the<00:02:08.550> role<00:02:08.700> of<00:02:08.729> blood
00:02:09.199 --> 00:02:09.209 align:start position:0%
understanding the role of blood
00:02:09.209 --> 00:02:11.570 align:start position:0%
understanding the role of blood
eosinophils<00:02:09.929> our<00:02:10.110> biomarker<00:02:10.890> in<00:02:11.489> the
00:02:11.570 --> 00:02:11.580 align:start position:0%
eosinophils our biomarker in the
00:02:11.580 --> 00:02:13.320 align:start position:0%
eosinophils our biomarker in the
beginning<00:02:11.910> that<00:02:12.150> was<00:02:12.360> not
00:02:13.320 --> 00:02:13.330 align:start position:0%
beginning that was not
00:02:13.330 --> 00:02:15.300 align:start position:0%
beginning that was not
the<00:02:13.420> road<00:02:13.660> that<00:02:13.870> was<00:02:14.080> choosing<00:02:14.560> foremost<00:02:15.070> at
00:02:15.300 --> 00:02:15.310 align:start position:0%
the road that was choosing foremost at
00:02:15.310 --> 00:02:17.940 align:start position:0%
the road that was choosing foremost at
pharmaceutical<00:02:16.060> companies<00:02:16.480> to<00:02:16.950> understand
00:02:17.940 --> 00:02:17.950 align:start position:0%
pharmaceutical companies to understand
00:02:17.950 --> 00:02:19.740 align:start position:0%
pharmaceutical companies to understand
that<00:02:18.160> at<00:02:18.370> the<00:02:18.400> response<00:02:18.910> to<00:02:19.030> treatment<00:02:19.480> but
00:02:19.740 --> 00:02:19.750 align:start position:0%
that at the response to treatment but
00:02:19.750 --> 00:02:22.590 align:start position:0%
that at the response to treatment but
later<00:02:20.050> on<00:02:20.250> parasitical<00:02:21.250> companies<00:02:21.700> develop
00:02:22.590 --> 00:02:22.600 align:start position:0%
later on parasitical companies develop
00:02:22.600 --> 00:02:26.010 align:start position:0%
later on parasitical companies develop
in<00:02:22.750> New<00:02:22.990> England<00:02:23.290> biological<00:02:24.270> choose<00:02:25.270> body
00:02:26.010 --> 00:02:26.020 align:start position:0%
in New England biological choose body
00:02:26.020 --> 00:02:28.530 align:start position:0%
in New England biological choose body
asana<00:02:26.350> fuels<00:02:26.590> has<00:02:27.130> been<00:02:27.400> made<00:02:27.640> biomarker<00:02:28.390> to
00:02:28.530 --> 00:02:28.540 align:start position:0%
asana fuels has been made biomarker to
00:02:28.540 --> 00:02:30.780 align:start position:0%
asana fuels has been made biomarker to
follow<00:02:28.810> those<00:02:29.050> patients<00:02:29.260> and<00:02:30.040> then<00:02:30.670> it
00:02:30.780 --> 00:02:30.790 align:start position:0%
follow those patients and then it
00:02:30.790 --> 00:02:33.480 align:start position:0%
follow those patients and then it
becomes<00:02:31.120> a<00:02:31.390> challenge<00:02:31.720> because<00:02:32.110> we<00:02:32.350> have<00:02:33.040> one
00:02:33.480 --> 00:02:33.490 align:start position:0%
becomes a challenge because we have one
00:02:33.490 --> 00:02:36.630 align:start position:0%
becomes a challenge because we have one
biomarker<00:02:34.090> which<00:02:35.040> predicts<00:02:36.040> responds<00:02:36.490> to
00:02:36.630 --> 00:02:36.640 align:start position:0%
biomarker which predicts responds to
00:02:36.640 --> 00:02:38.220 align:start position:0%
biomarker which predicts responds to
many<00:02:36.820> different<00:02:37.000> drugs<00:02:37.390> and<00:02:37.660> roland<00:02:38.080> bull
00:02:38.220 --> 00:02:38.230 align:start position:0%
many different drugs and roland bull
00:02:38.230 --> 00:02:40.500 align:start position:0%
many different drugs and roland bull
from<00:02:38.530> germany<00:02:38.890> then<00:02:39.150> gave<00:02:40.150> us<00:02:40.270> a<00:02:40.360> little
00:02:40.500 --> 00:02:40.510 align:start position:0%
from germany then gave us a little
00:02:40.510 --> 00:02:42.120 align:start position:0%
from germany then gave us a little
rundown<00:02:40.750> of<00:02:41.020> how<00:02:41.230> they<00:02:41.470> look<00:02:41.680> in<00:02:41.800> clinical
00:02:42.120 --> 00:02:42.130 align:start position:0%
rundown of how they look in clinical
00:02:42.130 --> 00:02:43.500 align:start position:0%
rundown of how they look in clinical
practice<00:02:42.160> to<00:02:42.520> try<00:02:42.820> and<00:02:42.940> work<00:02:43.060> out<00:02:43.240> which
00:02:43.500 --> 00:02:43.510 align:start position:0%
practice to try and work out which
00:02:43.510 --> 00:02:45.780 align:start position:0%
practice to try and work out which
patient<00:02:43.960> for<00:02:44.110> which<00:02:44.260> medicine<00:02:44.710> and<00:02:45.160> it<00:02:45.550> became
00:02:45.780 --> 00:02:45.790 align:start position:0%
patient for which medicine and it became
00:02:45.790 --> 00:02:47.520 align:start position:0%
patient for which medicine and it became
obvious<00:02:45.940> it<00:02:46.210> was<00:02:46.330> quite<00:02:46.570> difficult<00:02:46.810> and<00:02:47.380> there
00:02:47.520 --> 00:02:47.530 align:start position:0%
obvious it was quite difficult and there
00:02:47.530 --> 00:02:50.610 align:start position:0%
obvious it was quite difficult and there
was<00:02:47.620>